Literature DB >> 32118347

Comparable efficacy with similarly low risk of hypoglycaemia in patient- vs physician-managed basal insulin initiation and titration in insulin-naïve type 2 diabetic subjects: The Italian Titration Approach Study.

Riccardo C Bonadonna1, Andrea Giaccari2, Raffaella Buzzetti3, Gianluca Perseghin4, Domenico Cucinotta5, Angelo Avogaro6, Gianluca Aimaretti7, Monica Larosa8, Carmine G Fanelli9, Geremia B Bolli9.   

Abstract

AIMS: People with uncontrolled type 2 diabetes (T2DM) often delay initiating and titrating basal insulin. Patient-managed titration may reduce such deferral. The Italian Titration Approach Study (ITAS) compared the efficacy and safety of insulin glargine 300 U/mL (Gla-300) initiation and titration using patient- (nurse-supported) or physician-management in insulin-naïve patients with uncontrolled T2DM.
MATERIALS AND METHODS: ITAS was a multicentre, phase IV, 24-week, open-label, randomized (1:1), parallel-group study. Insulin-naïve adults with T2DM for ≥1 year with poor metabolic control initiated Gla-300 after discontinuation of SU/glinides, and were randomized to self-titrate insulin dose (nurse-assisted) or have it done by the physician. The primary endpoint was change in HbA1c . Secondary outcomes included hypoglycaemia incidence and rate, change in fasting self-monitored plasma glucose, patient-reported outcomes (PROs), and adverse events.
RESULTS: Three hundred and fifty five participants were included in the intention-to-treat population. At Week 24, HbA1c reduction from baseline was non-inferior in patient- vs physician-managed arms [least squares mean (LSM) change (SE): -1.60% (0.06) vs -1.49% (0.06), respectively; LSM difference: -0.11% (95% CI: -0.26 to 0.04)]. The incidence and rates of hypoglycaemia were similarly low in both arms: relative risk of confirmed and/or severe nocturnal (00:00-05:59 hours) hypoglycaemia was 0.77 (95% CI: 0.27 to 2.18). No differences were observed for improvement in PROs. No safety concerns were reported.
CONCLUSIONS: In the T2DM insulin-naïve, SU/glinides discontinued population, patient-managed (nurse-assisted) titration of Gla-300 may be a suitable option as it provides improved glycaemic control with low risk of hypoglycaemia, similar to physician-managed titration.
© 2020 SANOFI. Diabetes/Metabolism Research and Reviews published by John Wiley & Sons Ltd.

Entities:  

Keywords:  glargine 300 U/mL; glycaemic control; hypoglycaemia; insulin analogues; personalized medicine; randomized trial; type 2 diabetes

Year:  2020        PMID: 32118347     DOI: 10.1002/dmrr.3304

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  4 in total

1.  Efficacy and safety of patient-led versus physician-led titration of basal insulin in patients with uncontrolled type 2 diabetes: a meta-analysis of randomized controlled trials.

Authors:  Marco Castellana; Filippo Procino; Rodolfo Sardone; Pierpaolo Trimboli; Gianluigi Giannelli
Journal:  BMJ Open Diabetes Res Care       Date:  2020-07

2.  Does Gender Influence the Effectiveness and Safety of Insulin Glargine 300 U/ml in Patients with Uncontrolled Type 2 Diabetes? Results from the REALI European Pooled Analysis.

Authors:  Pierre Gourdy; Riccardo C Bonadonna; Nick Freemantle; Didac Mauricio; Dirk Müller-Wieland; Gregory Bigot; Celine Mauquoi; Alice Ciocca; Mireille Bonnemaire
Journal:  Diabetes Ther       Date:  2021-11-16       Impact factor: 2.945

3.  Underestimation of hypoglycaemia using patients' diaries compared with downloaded glucometer data: an ITAS post hoc analysis.

Authors:  Raffaella Buzzetti; Riccardo C Bonadonna; Andrea Giaccari; Gianluca Perseghin; Domenico Cucinotta; Carmine Fanelli; Angelo Avogaro; Gianluca Aimaretti; Monica Larosa; Ilaria Pacchetti; Geremia B Bolli
Journal:  Diabetes Obes Metab       Date:  2021-10-22       Impact factor: 6.408

4.  Patient-led rapid titration of basal insulin in gestational diabetes is associated with improved glycaemic control and lower birthweight.

Authors:  Andrew P McGovern; Kagabo D Hirwa; Abigail K Wong; Claire J E Holland; Isabelle Mayne; Aisha Hashimi; Rachael Thompson; Vicky Creese; Sarah Havill; Tina Sanders; Jennifer Blackman; Bijay Vaidya; Andrew T Hattersley
Journal:  Diabet Med       Date:  2022-08-08       Impact factor: 4.213

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.